Advances in Medicine (AIM) 2026 | Conference News and Highlights | MIMS TH

Advances in Medicine (AIM) 2026

Advances in Medicine (AIM) 2026

Hong Kong 30 May 2026 - 31 May 2026

Imaging helps refine diagnosis and management in PsA

Imaging helps refine diagnosis and management in PsA

Imaging complements clinical judgement in psoriatic arthritis (PsA) diagnosis and management, helping guide treatment to achieve remission or minimize disease progression, according to Professor Mikkel Østergaard of the University of Copenhagen, Denmark, who spoke at AIM 2026.

Imaging helps refine diagnosis and management in PsA

Multimodal strategies needed to halt progression of MCI and Alzheimer’s disease

Multimodal strategies needed to halt progression of MCI and Alzheimer’s disease

Early, long-term multimodal interventions are required to halt the progression of mild cognitive impairment (MCI) and Alzheimer’s disease, according to Professor Timothy Kwok of the Division of Geriatrics, Chinese University of Hong Kong (CUHK), who spoke at AIM 2026.

Multimodal strategies needed to halt progression of MCI and Alzheimer’s disease

04 Jun 2026

Donanemab delays Alzheimer's disease progression over 3 years

Donanemab delays Alzheimer's disease progression over 3 years

Donanemab administered for a limited duration continues to slow clinical progression in patients with early symptomatic Alzheimer’s disease (AD) over 3 years, according to Professor Chaur-Jong Hu of the Department of Neurology, Taipei Medical University, who spoke at Advances in Medicine (AIM) 2026.

Donanemab delays Alzheimer's disease progression over 3 years

04 Jun 2026

Something went wrong.